Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Kissei Snares Rigel’s AML Therapy in Japan, Korea, Taiwan
September 5, 2024
- Kidswell Is Open to M&As Amid Challenging Financing Environment: CEO
September 4, 2024
- PDRadiopharma’s PET Imaging Agent Amyvid Widens Label Too
September 4, 2024
- Asahi Kasei Closes Tender Offer for Calliditas, Enriches Renal Franchise
September 4, 2024
- Stella Pharma, NCC, Sumitomo Heavy Industries Tie Up in BNCT Basket Trial
September 4, 2024
- Aculys Pharma Files Diazepam Nasal Spray in Japan
September 3, 2024
- PET Agent Vizamyl Approved for Use in Patients on Anti-Aβ Therapy
September 3, 2024
- Nichi-Iko to Finally Roll Out Halaven AG Nearly 4 Years after Approval
September 3, 2024
- Ex-Sanofi Exec John Pulvar Tapped as New CEO of Ferring Japan
September 3, 2024
- BMS Aspires to Double Japan Sales over Next Decade with 5 Growth Drivers
September 3, 2024
- RaQualia’s Acid Reducer Tegoprazan Approved in Colombia
September 3, 2024
- Janssen Offloads Nizoral Cream to Teikoku Seiyaku
September 3, 2024
- Susmed Seeks Partial Change of Approval for Insomnia App towards Coverage
September 3, 2024
- Mounjaro Wins Podium in July GP Rep Promotion Rankings: Intage
September 3, 2024
- Takeda Shooting for Rail Transport Ratio of 60% in Modal Shift Push
September 2, 2024
- Takeda Pushes Back Shipping Date as Trucker Overtime Cap Hits Logistics
September 2, 2024
- Gilead, Cancer Institute Hospital Form R&D Partnership
September 2, 2024
- Pfizer Japan Seeks Partial Change of Champix’s Approval towards Re-Supply
September 2, 2024
- Pfizer Rolls Out Prevenar 20 in Japan, Pediatric NIP Set to Start October
September 2, 2024
- Mochida, Meiji Expand Epadel Sales Collab to ASEAN, Taiwan
September 2, 2024
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…